Rubinstein-Taybi Syndrome: Diagnostic and Management Approach
Diagnostic Testing
For suspected Rubinstein-Taybi syndrome, perform targeted molecular genetic testing for CREBBP and EP300 genes as the primary diagnostic approach, using FISH with five cosmid probes covering the entire CREBBP gene to detect microdeletions, followed by sequencing for point mutations if FISH is negative 1.
The diagnostic workup should follow this algorithmic approach:
Clinical Diagnosis
Look specifically for these cardinal features 1:
- Facial dysmorphisms: downslanting palpebral fissures, beaked nose with nasal septum extending below alae nasi, grimacing smile
- Distal limb anomalies: broad, angulated thumbs and halluces (big toes)
- Intellectual disability with global developmental delay
- Growth abnormalities: postnatal growth retardation, microcephaly
- Skeletal abnormalities: broad first digits, persistent fetal fingertip pads
Molecular Testing Strategy
The genetic testing should proceed systematically 2, 1:
FISH analysis using five cosmid probes covering the entire CREBBP gene (not just the commonly used 3' RT1 probe, which misses 50% of microdeletions including 5' and interstitial deletions) - detects approximately 14-16% of cases 2
Sequencing of CREBBP and EP300 genes if FISH is negative - identifies point mutations, small deletions, and splice site mutations in approximately 55-78% of clinically diagnosed cases 3, 1
Protein truncation test can identify truncating mutations, though only detects ~11% of cases 2
Critical pitfall: Using only the 3' probe RT1 in FISH will miss approximately half of all microdeletions 2. The five-probe approach is essential for comprehensive deletion screening.
Multidisciplinary Management
Implement a comprehensive surveillance and intervention program addressing the high-burden comorbidities, with particular attention to gastrointestinal issues (present in 54% of patients), growth monitoring, and early gastrostomy tube placement when feeding difficulties compromise nutritional status 4, 5.
Systematic Management by Organ System
Gastrointestinal Management 4
- Screen proactively for: constipation (most common), gastroesophageal reflux, dysphagia, vomiting, feeding intolerance
- Diagnostic evaluations: upper GI imaging, video swallow studies, esophagogastroduodenoscopy as indicated
- Gastrostomy tube consideration: Nearly 50% require G-tube support, typically placed in later childhood. This intervention demonstrates significant improvements in weight and BMI z-scores, with successful transitions to partial or full oral intake possible in some cases
- Key point: GI symptoms frequently predate genetic diagnosis, so maintain high index of suspicion
Growth and Nutrition 5, 4
- Serial growth parameter monitoring (height, weight, head circumference)
- Early nutritional intervention for failure to thrive
- Consider G-tube placement proactively rather than reactively when oral intake is inadequate
Neurodevelopmental and Psychiatric 5, 6
- Early intervention services for developmental delays
- Special education planning
- Screen for and manage psychiatric comorbidities (anxiety, behavioral issues)
- Intellectual disability support services
Skeletal and Orthopedic 5
- Monitor for scoliosis
- Assess joint laxity and instability
- Orthopedic consultation for thumb/toe abnormalities if functional impairment
Cardiac 5
- Echocardiography for congenital heart defects
- Cardiology follow-up as indicated
Ophthalmologic 5
- Regular vision screening
- Assess for refractive errors, strabismus, nasolacrimal duct obstruction
Dental 5
- Preventive dental care
- Management of dental crowding and malocclusion
Other Surveillance 5
- Hearing evaluation
- Renal ultrasound (increased risk of structural abnormalities)
- Tumor surveillance (slightly increased risk of certain malignancies)
Care Coordination
Establish a medical home with a designated care coordinator to manage the complex, time-consuming healthcare needs, as over 90% of individuals with RTS survive to adulthood requiring lifelong multidisciplinary care 7, 1.
The 2024 international consensus statement 1 represents the most authoritative guidance, emphasizing that clinical practice has been heterogeneous globally, but standardized approaches improve outcomes. Earlier guidelines from 2003 5 provided the foundational surveillance framework that remains relevant, though the 2024 consensus updates diagnostic criteria and molecular testing approaches.
Quality of life considerations: Physical and social functioning are most impaired domains, with QOL declining with age 8. Early, aggressive management of feeding issues, developmental support, and family-centered care planning are essential to optimize long-term outcomes.